Physician profile
Joseph Barnthouse
NPI 1215968433
$519.35
in general payments reported to CMS, 2019-2025
5 companies · $15.14 in 2025
The $15.14 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $76.80 · 2021: $192 · 2022: $32.13 · 2024: $38.38 · 2025: $15.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $53.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $53.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sientra, INC. | $403.24 | 2019-2021 | |
| Galderma Laboratories, L.P. | $53.15 | 2020-2024 | |
| Solta Medical, A Division of Bausch Health US, LLC | $36.45 | 2024-2025 | |
| Mentor Worldwide LLC | $26.51 | 2021-2022 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$2,709,265.47 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Barnthouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.